Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Change in Working Capital · Q3 FY2026 · quarter ended Sep 2026

Change in working capital turns negative

Q3 FY2026 change in working capital was -$872K, compared with $9.8M a year earlier. Trailing-twelve-month change in working capital was $20.49M.

Context

  • Change in working capital amounted to 937.2% of revenue in FY2025, up 629.5 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near -$872K or moves back toward the trailing-twelve-month quarterly average of $5.12M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$872K-110.3% QoQ
Last fiscal yearDec 2025
$14.06M+165.1% YoY
LTMSep 2026
$20.49M+58.8% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.9%——
1 year+165.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
14.06M USD
Year-over-year change
+165.1%

Change in Working Capital vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 change in working capital of $20.49M is the 3rd largest of the 10 companies compared; the peer median is $558.59K.
  • Its year-over-year change of +58.8% is the 5th highest of 8, against a peer median of +67.2%.
  • Change in working capital amounts to 18293.8% of revenue for CLDX, versus a peer median of 7.2%.
CLDX Competitors Peer median
Change in Working Capital for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$87M -18.7%—74.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$50.82M +271.7%+18.4%7.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$20.49M +58.8%—18293.8%
MGNXMacroGenics, Inc.LTM Mar 2026$17.87M +67.2%+66.6%11.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$4.47M +184.8%——
IMNMImmunome, Inc.LTM Sep 2026$3.22M +124.5%——
XNCRXencor, Inc.LTM Jun 2026$2.5M -91.4%-1.0%2.4%
AGENAgenus Inc.LTM Mar 2026$1.39M -106.1%+4.3%1.1%
ADAGAdagene Inc.LTM Jun 2024$558.59K ——68.5%
CGENCompugen Ltd.LTM Dec 2025$0 —-1.2%0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $558.59K+67.2%+4.3%7.2%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.76M)
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
Deferred Income Tax(227K)0000
Stock-Based Compensation8.95M023.89M34.24M36.22M
Change in Working Capital(1.05M)(3.9M)13.46M(21.6M)14.06M
Accounts Receivables1.57M(175K)(2.28M)1.93M(1.32M)
Inventory00000
Accounts Payables3.65M3.12M9.38M11.63M11.03M
Other Working Capital(6.28M)(6.85M)6.36M(35.16M)4.34M
Other Non-Cash Items(1.14M)9.6M(6.22M)(15.73M)(5.84M)
Operating Cash Flow(60.91M)(103.73M)(107.29M)(157.78M)(210.95M)
Capital Expenditures(1.25M)(1.83M)(1.82M)(1.92M)(2.71M)
Acquisitions (Net)27K69K000
Purchases of Investments(389.88M)(188.97M)(424.56M)(789.92M)(384.5M)
Sales of Investments174.95M280.67M320.6M501.71M596.29M
Other Investing Activities00000
Investing Cash Flow(216.16M)89.94M(105.78M)(290.13M)209.07M
Debt Repayment00000
Common Stock Issued269.89M4.08M216.22M432.3M2.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.48M02.24M9.15M0
Financing Cash Flow272.37M4.08M218.46M441.45M2.39M
Effect of Forex Changes00000
Net Change in Cash(4.69M)(9.71M)5.39M(6.46M)515K
Free Cash Flow(62.16M)(105.56M)(109.11M)(159.7M)(213.66M)

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.